{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:55:27Z","timestamp":1782896127198,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K12244"],"award-info":[{"award-number":["25K12244"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10147-025-02827-w","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T21:19:12Z","timestamp":1751923152000},"page":"1858-1865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world trends in the use and outcomes of novel androgen receptor signaling inhibitor therapy in patients with non-metastatic castration-resistant prostate cancer: a multicenter retrospective study"],"prefix":"10.1007","volume":"30","author":[{"given":"Fumiya","family":"Yoneyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8284-9582","authenticated-orcid":false,"given":"Naoki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanao","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuma","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikari","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyo","family":"Togashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Horiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Noro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"2827_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"2827_CR2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00345-013-1157-5","volume":"32","author":"LA Kluth","year":"2014","unstructured":"Kluth LA, Shariat SF, Kratzik C et al (2014) The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. World J Urol 32:669\u2013676. https:\/\/doi.org\/10.1007\/s00345-013-1157-5","journal-title":"World J Urol"},{"key":"2827_CR3","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/jco.2005.01.529","volume":"23","author":"MR Smith","year":"2005","unstructured":"Smith MR, Kabbinavar F, Saad F et al (2005) Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23:2918\u20132925. https:\/\/doi.org\/10.1200\/jco.2005.01.529","journal-title":"J Clin Oncol"},{"key":"2827_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","volume":"79","author":"MR Smith","year":"2021","unstructured":"Smith MR, Saad F, Chowdhury S et al (2021) Apalutamide and overall survival in prostate cancer. Eur Urol 79:150\u2013158. https:\/\/doi.org\/10.1016\/j.eururo.2020.08.011","journal-title":"Eur Urol"},{"key":"2827_CR5","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","volume":"382","author":"CN Sternberg","year":"2020","unstructured":"Sternberg CN, Fizazi K, Saad F et al (2020) Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 382:2197\u20132206. https:\/\/doi.org\/10.1056\/NEJMoa2003892","journal-title":"N Engl J Med"},{"key":"2827_CR6","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","volume":"383","author":"K Fizazi","year":"2020","unstructured":"Fizazi K, Shore N, Tammela TL et al (2020) Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 383:1040\u20131049. https:\/\/doi.org\/10.1056\/NEJMoa2001342","journal-title":"N Engl J Med"},{"key":"2827_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13091661","author":"K Nakane","year":"2023","unstructured":"Nakane K, Watanabe H, Naiki T et al (2023) Trends in the use of second-generation androgen receptor axis inhibitors for metastatic hormone-sensitive prostate cancer and clinical factors predicting biological recurrence. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics13091661","journal-title":"Diagnostics"},{"key":"2827_CR8","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1111\/iju.15550","volume":"31","author":"H Miura","year":"2024","unstructured":"Miura H, Hatakeyama S, Tabata R et al (2024) Treatment trends in patients with de novo metastatic prostate cancer in the era of upfront combination therapy. Int J Urol 31:1330\u20131336. https:\/\/doi.org\/10.1111\/iju.15550","journal-title":"Int J Urol"},{"key":"2827_CR9","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1080\/14796694.2024.2373681","volume":"20","author":"U Swami","year":"2024","unstructured":"Swami U, Hong A, Diessner B et al (2024) Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States. Future Oncol 20:2467\u20132480. https:\/\/doi.org\/10.1080\/14796694.2024.2373681","journal-title":"Future Oncol"},{"key":"2827_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/13696998.2024.2320001","volume":"27","author":"Y Wang","year":"2024","unstructured":"Wang Y, Liu C, Liu C et al (2024) Treatment patterns and healthcare resource utilization in patients with metastatic hormone-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer in China: a real-world observational study. J Med Econ 27:361\u2013369. https:\/\/doi.org\/10.1080\/13696998.2024.2320001","journal-title":"J Med Econ"},{"key":"2827_CR11","doi-asserted-by":"publisher","first-page":"e17042","DOI":"10.1200\/JCO.2022.40.16_suppl.e17042","volume":"40","author":"AS Halwani","year":"2022","unstructured":"Halwani AS, Patil V, Morreall D et al (2022) Real-world treatment patterns among veterans with nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol 40:e17042\u2013e17042. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.e17042","journal-title":"J Clin Oncol"},{"key":"2827_CR12","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/jco.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM et al (2016) Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 34:1402\u20131418. https:\/\/doi.org\/10.1200\/jco.2015.64.2702","journal-title":"J Clin Oncol"},{"key":"2827_CR13","doi-asserted-by":"publisher","unstructured":"Arlen PM, Bianco F, Dahut WL, et al (2008) Prostate Specific Antigen Working Group Guidelines on prostate specific antigen doubling time. J Urol 179:2181\u20132185; discussion 2185\u20132186 https:\/\/doi.org\/10.1016\/j.juro.2008.01.099","DOI":"10.1016\/j.juro.2008.01.099"},{"key":"2827_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70226","volume":"13","author":"H Miura","year":"2024","unstructured":"Miura H, Yamamoto H, Okuyama Y et al (2024) Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer. Cancer Med 13:e70226. https:\/\/doi.org\/10.1002\/cam4.70226","journal-title":"Cancer Med"},{"key":"2827_CR15","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.euo.2023.11.013","volume":"7","author":"NJ Sathianathen","year":"2024","unstructured":"Sathianathen NJ, Lawrentschuk N, Konety B et al (2024) Cost effectiveness of systemic treatment intensification for metastatic hormone-sensitive prostate cancer: is triplet therapy cost effective? Eur Urol Oncol 7:870\u2013876. https:\/\/doi.org\/10.1016\/j.euo.2023.11.013","journal-title":"Eur Urol Oncol"},{"key":"2827_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30168-1","volume":"6","author":"H Ureshino","year":"2019","unstructured":"Ureshino H, Kamachi K, Kimura S (2019) Japan\u2019s high-cost medical expense benefit system could be an obstacle to promoting generic imatinib. Lancet Haematol 6:e498. https:\/\/doi.org\/10.1016\/S2352-3026(19)30168-1","journal-title":"Lancet Haematol"},{"key":"2827_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.29783","volume":"7","author":"DJ George","year":"2024","unstructured":"George DJ, Morgans AK, Constantinovici N et al (2024) Androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. JAMA Netw Open 7:e2429783. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.29783","journal-title":"JAMA Netw Open"},{"key":"2827_CR18","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s10147-024-02548-6","volume":"29","author":"S Hara","year":"2024","unstructured":"Hara S, Mori K, Fukuokaya W et al (2024) Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study. Int J Clin Oncol 29:1191\u20131197. https:\/\/doi.org\/10.1007\/s10147-024-02548-6","journal-title":"Int J Clin Oncol"},{"key":"2827_CR19","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s10147-021-02070-z","volume":"27","author":"A Yokomizo","year":"2022","unstructured":"Yokomizo A, Yonese J, Egawa S et al (2022) Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan. Int J Clin Oncol 27:418\u2013426. https:\/\/doi.org\/10.1007\/s10147-021-02070-z","journal-title":"Int J Clin Oncol"},{"key":"2827_CR20","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s00345-022-03963-y","volume":"40","author":"S Narita","year":"2022","unstructured":"Narita S, Kimura T, Hatakeyama S et al (2022) Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy. World J Urol 40:1135\u20131141. https:\/\/doi.org\/10.1007\/s00345-022-03963-y","journal-title":"World J Urol"},{"key":"2827_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102115","volume":"22","author":"DE O\u2019Sullivan","year":"2024","unstructured":"O\u2019Sullivan DE, Kolinsky MP, Shokar S et al (2024) A real world observational study characterizing patients with advanced prostate cancer treated with or without androgen receptor-pathway-inhibitor therapies in Alberta, Canada. Clin Genitourin Cancer 22:102115. https:\/\/doi.org\/10.1016\/j.clgc.2024.102115","journal-title":"Clin Genitourin Cancer"},{"key":"2827_CR22","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1007\/s11255-024-04116-3","volume":"56","author":"T Shimomura","year":"2024","unstructured":"Shimomura T, Mori K, Ito K et al (2024) Docetaxel versus androgen receptor signaling inhibitor (ARSI) against chemo-na\u00efve castration-resistant prostate cancer (CRPC): propensity score matched analysis in real world. Int Urol Nephrol 56:3719\u20133725. https:\/\/doi.org\/10.1007\/s11255-024-04116-3","journal-title":"Int Urol Nephrol"},{"key":"2827_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.39434","volume":"7","author":"S Roy","year":"2024","unstructured":"Roy S, Malone S, Wing K et al (2024) Prior local therapy and first-line apalutamide in patients with nonmetastatic castration-resistant prostate cancer: a secondary analysis of the SPARTAN randomized clinical trial. JAMA Netw Open 7:e2439434. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.39434","journal-title":"JAMA Netw Open"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02827-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02827-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02827-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T14:07:57Z","timestamp":1756390077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02827-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2827"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02827-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6441263\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"13 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shingo Hatakeyama received honoraria from Janssen Pharmaceutical K.K., Astellas Pharma Inc., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Bayer AG, Pfizer Inc., Bristol-Myers Squibb, Merck Biopharma Co., Ltd., Kaneka Corporation, and Nipro Corporation. The other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study adhered to the principles of the Declaration of Helsinki and was approved by the ethics committees of the Hirosaki University Graduate School of Medicine (authorization number: 2019-099-1 and 2021-158-2) and all participating hospitals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The requirement for written informed consent was waived because of the use of a public disclosure of study information (opt-out approach).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}